

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4502730
<b>Application Number:</b>	10581656
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3937
<b>Title of Invention:</b>	Oligonucleotides Derived From Mycobacterium for Stimulating Immune Function, Treating Immune-Related Diseases, Atopic Dermatitis and/or Protecting Normal Immune Cell
<b>First Named Inventor/Applicant Name:</b>	Hyung-Joo Kwon
<b>Customer Number:</b>	72960
<b>Filer:</b>	Tanya A Arenson/Jasmine Stansberry
<b>Filer Authorized By:</b>	Tanya A Arenson
<b>Attorney Docket Number:</b>	BARUN-10974
<b>Receipt Date:</b>	22-DEC-2008
<b>Filing Date:</b>	09-JUN-2008
<b>Time Stamp:</b>	16:36:16
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	2799
Deposit Account	504302
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		RRR_10974.pdf	103536 82c0a0f1a2d45c5b85179629a8a0fbc0919c210	yes	5
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Amendment/Req. Reconsideration-After Non-Final Reject		1		1
	Claims		2		3
	Applicant Arguments/Remarks Made in an Amendment		4		5
<b>Warnings:</b>					
<b>Information:</b>					
2	Information Disclosure Statement Letter	IDSletter.pdf	75580 890d2d62c0d5a1e0f9a58a21eb0bc73303f58f9	no	2
<b>Warnings:</b>					
<b>Information:</b>					
3	Information Disclosure Statement (IDS) Filed (SB/08)	SB08.pdf	609609 b9888b10f19121572d480c97b79d91cc79620c1	no	5
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	KLINMAN1996PNASVol93pp2879-83.pdf	1093373 430741c1b874942172487e607b1355596f7676c	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	AKDIS2000CurrOpinImmunolVol12pp641-6.pdf	1574294 d1d2d670d1ff52f8b3251a65b658e0ef35476c79	no	9
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	KWON2003BiochemBiophysResVol311pp129-38.pdf	1831873 4b480b0e09e1407b3d54875a0d17d7f4d5f1f0d3	no	13
<b>Warnings:</b>					

Information:					
7	NPL Documents	PROSSER1976IntJRadiatEcolVol130pp459-65.pdf	700484 b679380db6c4a1e87b1d419d7c530d13d07	no	10
Warnings:					
Information:					
8	NPL Documents	ASHWELL1986JImmunolVol136pp3649-56.pdf	1737143 b529b5c1b8b577b2929a5d8c97f7c8b83e9	no	11
Warnings:					
Information:					
9	NPL Documents	IMOKAWA1991JInvestDermatolVol96pp523-6.pdf	936494 a043c9e40b6572c3c3680a015c8c50f7fb90a	no	7
Warnings:					
Information:					
10	NPL Documents	RUDI KOFF1998LancetVol351pp1717.pdf	1639437 150ab18ba666c5e5ae20c00c7170cc517d6c3d31	no	9
Warnings:					
Information:					
11	NPL Documents	KRIEG2005NatureVol374pp546-9-fromAUCase.pdf	1057559 c52a1e629b1f3ba79bbad3abab5e1445d3c76c	no	4
Warnings:					
Information:					
12	NPL Documents	KRIEG2002AnnuRevImmunolVol20pp709-60-fromAU-CNcase.pdf	5028400 6048145bf020e912cad686b729626570c8b7c3a	no	34
Warnings:					
Information:					
13	NPL Documents	UHLMANN2003CurrOpinDrugDiscDevVol6pp204-17-FromEPcase.pdf	2744091 11ebc9bc2e4e1ad4d3d1843245541b47b5d4b409	no	14
Warnings:					
Information:					
14	NPL Documents	KRIEG-Univlowapp1-22-fromEPcase.pdf	2479860 1298be113481c4c59dcefbf17ac0020132a7832	no	22
Warnings:					
Information:					
15	Foreign Reference	WO199840100-FromEPcase.pdf	2746432 97bc1761e1139a19ab489c348d59534d87da0c7	no	69
Warnings:					

Information:					
16	NPL Documents	DAVIS1998JImmunolVol160pp 870-6.pdf	164105 <small>520M055dec3499846cf53b18f1438aeb37962</small>	no	7
Warnings:					
Information:					
17	NPL Documents	TANAKA1992Vol175pp597-607. pdf	1345093 <small>9c4e977191bce79c2b6fd118ba162Bc0ffce405</small>	no	11
Warnings:					
Information:					
18	NPL Documents	DENG2000ArthritisRheumatism Vol43pp356-64.pdf	937965 <small>e91e92a039818f76e73b77363c70f538ee5137a</small>	no	9
Warnings:					
Information:					
19	NPL Documents	BALLAS1996JImmunolVol157p p1840-5-1.pdf	574316 <small>1d983ce1d883ae34d5ec296ae23ad168727b26c3</small>	no	6
Warnings:					
Information:					
20	NPL Documents	KUBOTA2004JRadiatResVol45p p205-11SCANNED.pdf	564459 <small>ca2cd3d8ee418bafcf3125c24c3a78b75a29b35</small>	no	7
Warnings:					
Information:					
21	Fee Worksheet (PTO-06)	fee-info.pdf	30649 <small>e14da1a1bb1ed3203ee06ae205c338268991285</small>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			27974752		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.